Literature DB >> 28199774

Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis.

Tatsunori Hanai1, Makoto Shiraki1, Satoshi Watanabe1, Takahiro Kochi1, Kenji Imai1, Atsushi Suetsugu1, Koji Takai1,2, Hisataka Moriwaki1, Masahito Shimizu1.   

Abstract

AIM: Minimal hepatic encephalopathy (MHE) and sarcopenia impair the health-related quality of life and prognosis of patients with liver cirrhosis; however, the relationship between MHE and sarcopenia remains unclear. The aim of this study was to investigate their relationship and to identify the predictors of MHE in cirrhotic patients.
METHODS: This retrospective study evaluated 120 cirrhotic patients who were tested for MHE and sarcopenia. Minimal hepatic encephalopathy was diagnosed by using the computer-aided neuropsychiatric test. Sarcopenia was diagnosed based on the assessment criteria recommended by the Japan Society of Hepatology. Muscle mass and muscle strength were measured by using bio-impedance analysis and digital grip strength dynamometer. Univariate and multivariate logistic regression analyses were carried out to identify the predictors of MHE.
RESULTS: Of the 120 cirrhotic patients, 28 (23%) and 32 (27%) were diagnosed with MHE and sarcopenia, respectively. The prevalence of MHE was higher in patients with sarcopenia than in those without sarcopenia (P = 0.01). By the univariate analysis, MHE was significantly complicated with sarcopenia (P < 0.01). In the multivariate analysis, sarcopenia (odds ratio = 3.31, 95% confidence interval = 1.19-9.42; P = 0.02) and serum branched-chain amino acids levels <327 nmol/mL (odds ratio = 2.98, 95% confidence interval = 1.08-8.34; P = 0.03) were found to be associated with MHE.
CONCLUSIONS: Sarcopenia and serum branched-chain amino acids levels were predictors of MHE. The amelioration of sarcopenia and/or amino acids imbalance may improve MHE in patients with liver cirrhosis.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  cirrhosis; minimal hepatic encephalopathy; sarcopenia; skeletal muscle

Year:  2017        PMID: 28199774     DOI: 10.1111/hepr.12873

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  27 in total

1.  Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.

Authors:  Rahima A Bhanji; Carlos Moctezuma-Velazquez; Andres Duarte-Rojo; Maryam Ebadi; Sunita Ghosh; Christopher Rose; Aldo J Montano-Loza
Journal:  Hepatol Int       Date:  2018-06-07       Impact factor: 6.047

2.  A Comparison of Different Frailty Scores and Impact of Frailty on Outcome in Patients With Cirrhosis.

Authors:  Surender Singh; Sunil Taneja; Puneeta Tandon; Akash Bansal; Ujjwal Gorsi; Akash Roy; Arka De; Nipun Verma; Madhumita Premkumar; Ajay Duseja; Radha K Dhiman; Virendra Singh
Journal:  J Clin Exp Hepatol       Date:  2021-07-21

3.  The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Stefania Gioia; Lorenzo Ridola; Ludovica Cristofaro; Manuela Merli; Jessica Faccioli; Oliviero Riggio; Silvia Nardelli
Journal:  Liver Int       Date:  2021-09-28       Impact factor: 8.754

4.  Low Levels of Serum Zinc Associate with Malnutrition Risk Assessed by the Royal Free Hospital-Nutritional Prioritizing Tool in Cirrhosis.

Authors:  Wanting Yang; Xiaoyu Wang; Zihan Yu; Chaoqun Li; Mingyu Sun; Yifan Li; Yangyang Hui; Gaoyue Guo; Xiaofei Fan; Kui Jiang; Chao Sun
Journal:  Biol Trace Elem Res       Date:  2021-11-17       Impact factor: 4.081

5.  The profiling of plasma free amino acids and the relationship between serum albumin and plasma-branched chain amino acids in chronic liver disease: a single-center retrospective study.

Authors:  Akitoshi Sano; Eiji Kakazu; Tatsuki Morosawa; Jun Inoue; Takayuki Kogure; Masashi Ninomiya; Tomoaki Iwata; Teruyuki Umetsu; Takuya Nakamura; Satoshi Takai; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-01-27       Impact factor: 7.527

Review 6.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

Review 7.  Sarcopenia and Frailty in Liver Cirrhosis.

Authors:  Hiroki Nishikawa; Shinya Fukunishi; Akira Asai; Shuhei Nishiguchi; Kazuhide Higuchi
Journal:  Life (Basel)       Date:  2021-04-27

8.  Relationship between skeletal muscle mass and liver fibrosis markers for patients with hepatitis C virus related liver disease.

Authors:  Ryo Takata; Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Akio Ishii; Yuho Miyamoto; Noriko Ishii; Yukihisa Yuri; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 9.  Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.

Authors:  Segundo Moran; Marlene López-Sánchez; María Del Pilar Milke-García; Gustavo Rodríguez-Leal
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

10.  Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial.

Authors:  Tomomi Okubo; Masanori Atsukawa; Akihito Tsubota; Hiroki Ono; Tadamichi Kawano; Yuji Yoshida; Taeang Arai; Korenobu Hayama; Norio Itokawa; Chisa Kondo; Keiko Kaneko; Katsuhiko Iwakiri
Journal:  Nutrients       Date:  2021-05-30       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.